The Medical Letter on Drugs and Therapeutics
October 23, 2006
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Ranibizumab (Lucentis) for Macular Degeneration
October 23, 2006 (Issue: 1246)The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab (Avastin), which is FDA-approved for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.